Moreover, SREBP as well as ATP Citrate Lyase (ACLY), a downstream target of SREBP, have been found to be upregulated in glioblastoma, colorectal cancer, breast cancer, non-small cell lung cancer, and hepatocellular carcinoma (de Gonzalo-Calvo et al., 2015; Guillaumond et al., 2015). Here, ACLY is linked to breast cancer.